Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Condition:   Medullary Thyroid Cancer (MTC)
Intervention:   Drug: Pembrolizumab
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified February 23, 2017

http://ift.tt/2lYI0G0